PIPAC technology from REGER for clinics and medical professionals
The treatment of peritoneal carcinomatosis requires the utmost precision and maximum care for the patient. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has proven itself in specialized centers as an established, minimally invasive method for the local application of chemotherapeutic agents.
Reger has had a significant influence on this form of therapy through his technological developments. The focus is on PIPAC nebulization systems with the QuattroJet® nozzle, which was developed for uniform, reproducible aerosol distribution throughout the peritoneal cavity. The innovative multi-jet design supports optimized distribution of active ingredients and creates the basis for standardized, safe, and efficient application conditions in the operating room. Reger solutions offer decisive advantages, particularly in the context of hospital reform, which focuses on specialization, traceable quality, and performance-based structures: They enable reproducible processes in highly specialized centers and support hospitals in confidently meeting future quality and structural requirements.
Technical features of REGER PIPAC nebulizers
REGER systems are designed to support the special requirements of intraperitoneal aerosol administration:
- Controlled aerosol generation under pneumoperitoneal pressure conditions
- Defined droplet sizes for even distribution
- Robust construction for use in the operating room
- Simple, easy-to-understand handling for the surgical team
The systems integrate into standard laparoscopic setups and can be incorporated into existing surgical procedures.
QuattroJet® in clinical use
REGER’s QuattroJet® technology was developed to enable multidirectional aerosol distribution in the peritoneal cavity. Characteristic features:
- Four outlet nozzles for wider spatial distribution
- Homogeneous distribution of the aerosol throughout the peritoneal cavity
- Reduction of shadowing effects compared to unidirectional systems
- Clinically validated improvement in drug distribution
The goal is a standardizable, reproducible application process that meets the quality and safety requirements in surgical oncology.
The benchmark in PIPAC development
Reger stands for progress in PIPAC technology like no other name. Extensive studies confirm the clinical value of the procedure and reflect the intensive development work that has gone into it. With its deep understanding of the process and continuous innovation, Reger maintains its position as a leading developer and driving force in the field of PIPAC.
Introduce with guidance. Use safely.
Reger supports clinics and surgical teams with a comprehensive service package for the introduction of PIPAC therapy. In close cooperation with the German PIPAC Center, the introduction is structured, practical, and quality-oriented. In this way, Reger creates the ideal conditions for safe operation, high acceptance within the team, and a successful start in everyday clinical practice.
Training, support, and collaboration
To support safe use, REGER offers:
- Technical briefings for surgical teams
- Support in creating internal SOPs (Standard Operating Procedures) for using the systems.
- Support for pilot projects and introduction of the technology
- Implementation program and long-term support
Upon request, contact can also be established with centers experienced in PIPAC to facilitate the exchange of experiences between users.
Michael Häfele
Sales Manager
E-Mail: m.haefele@reger-med.de
Phone: +49 176 4332 8487